• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
The natural course of COVID-19 patients without clinical intervention.COVID-19 患者在未经临床干预情况下的自然病程。
J Med Virol. 2021 Sep;93(9):5527-5537. doi: 10.1002/jmv.27087. Epub 2021 May 19.
2
Lymphocyte subset alterations with disease severity, imaging manifestation, and delayed hospitalization in COVID-19 patients.淋巴细胞亚群改变与 COVID-19 患者的疾病严重程度、影像学表现和延迟住院有关。
BMC Infect Dis. 2021 Jul 1;21(1):631. doi: 10.1186/s12879-021-06354-7.
3
Prediction and follow-up of risk factors for severe SARS-CoV-2 pneumonia and application of CT visual scoring.预测和随访严重 SARS-CoV-2 肺炎的危险因素及 CT 视觉评分的应用。
Technol Health Care. 2021;29(S1):153-164. doi: 10.3233/THC-218016.
4
Clinical characteristics and risk factors for severity of COVID-19 outside Wuhan: a double-center retrospective cohort study of 213 cases in Hunan, China.中国湖南两中心回顾性队列研究 213 例病例:武汉以外地区 COVID-19 严重程度的临床特征和危险因素。
Ther Adv Respir Dis. 2020 Jan-Dec;14:1753466620963035. doi: 10.1177/1753466620963035.
5
Multicenter Study of Temporal Changes and Prognostic Value of a CT Visual Severity Score in Hospitalized Patients With Coronavirus Disease (COVID-19).多中心研究:住院的新型冠状病毒肺炎(COVID-19)患者 CT 视觉严重程度评分的时间变化及其预后价值。
AJR Am J Roentgenol. 2021 Jul;217(1):83-92. doi: 10.2214/AJR.20.24044. Epub 2020 Sep 9.
6
Prognostic value of neutrophil-to-lymphocyte ratio, lactate dehydrogenase, D-dimer, and computed tomography score in patients with coronavirus disease 2019.中性粒细胞与淋巴细胞比值、乳酸脱氢酶、D-二聚体和计算机断层扫描评分对新型冠状病毒肺炎患者的预后价值。
Aging (Albany NY). 2021 Sep 8;13(17):20896-20905. doi: 10.18632/aging.203501.
7
Early risk factors of the exacerbation of coronavirus disease 2019 pneumonia.新型冠状病毒肺炎恶化的早期危险因素。
J Med Virol. 2020 Nov;92(11):2593-2599. doi: 10.1002/jmv.26071. Epub 2020 Aug 21.
8
Predictive role of clinical features in patients with coronavirus disease 2019 for severe disease.2019冠状病毒病患者临床特征对重症疾病的预测作用
Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2020 May 28;45(5):536-541. doi: 10.11817/j.issn.1672-7347.2020.200384.
9
Clinical progression and changes of chest CT findings among asymptomatic and pre-symptomatic patients with SARS-CoV-2 infection in Wuhan, China.中国武汉无症状和出现症状前期 SARS-CoV-2 感染患者的临床进展和胸部 CT 表现变化。
Expert Rev Respir Med. 2021 Mar;15(3):411-417. doi: 10.1080/17476348.2021.1840358. Epub 2020 Nov 2.
10
[Spatial and temporal distribution and predictive value of chest CT scoring in patients with COVID-19].新型冠状病毒肺炎患者胸部CT评分的时空分布及预测价值
Zhonghua Jie He He Hu Xi Za Zhi. 2021 Mar 12;44(3):230-236. doi: 10.3760/cma.j.cn112147-20200522-00626.

引用本文的文献

1
Effect of noninvasive ventilation on mortality and clinical outcomes among patients with severe hypoxemic COVID-19 pneumonia after high-flow nasal oxygen failure: a multicenter retrospective French cohort with propensity score analysis.高流量鼻氧失败后严重低氧血症 COVID-19 肺炎患者无创通气对死亡率和临床结局的影响:一项采用倾向性评分分析的多中心回顾性法国队列研究。
Respir Res. 2024 Jul 15;25(1):279. doi: 10.1186/s12931-024-02873-4.
2
SUPER Score Contributes to Warning and Management in Early-Stage COVID-19.SUPER评分有助于早期新冠肺炎的预警与管理。
Infect Med (Beijing). 2023 Oct 19;2(4):308-314. doi: 10.1016/j.imj.2023.09.003. eCollection 2023 Dec.
3
Three-Day Icatibant on Top of Standard Care in Patients With Coronavirus Disease 2019 Pneumonia: A Randomized, Open-Label, Phase 2, Proof-of-Concept Trial.COVID-19 肺炎患者标准治疗上加用 3 天依卡替班特治疗:一项随机、开放标签、2 期、概念验证试验。
Clin Infect Dis. 2023 May 24;76(10):1784-1792. doi: 10.1093/cid/ciac984.
4
Current utilization of interferon alpha for the treatment of coronavirus disease 2019: A comprehensive review.当前干扰素 α 在治疗 2019 冠状病毒病中的应用:全面综述。
Cytokine Growth Factor Rev. 2022 Feb;63:34-43. doi: 10.1016/j.cytogfr.2022.01.001. Epub 2022 Jan 13.

本文引用的文献

1
COVID-19 and cancer: From basic mechanisms to vaccine development using nanotechnology.新型冠状病毒肺炎与癌症:从基本机制到利用纳米技术进行疫苗开发
Int Immunopharmacol. 2021 Jan;90:107247. doi: 10.1016/j.intimp.2020.107247. Epub 2020 Dec 2.
2
Clinical characteristics and antibiotics treatment in suspected bacterial infection patients with COVID-19.疑似 COVID-19 细菌感染患者的临床特征和抗生素治疗。
Int Immunopharmacol. 2021 Jan;90:107157. doi: 10.1016/j.intimp.2020.107157. Epub 2020 Nov 3.
3
Epidemiology of SARS-CoV-2.SARS-CoV-2 的流行病学。
Infection. 2021 Apr;49(2):233-239. doi: 10.1007/s15010-020-01531-3. Epub 2020 Oct 8.
4
Dynamic CT assessment of disease change and prognosis of patients with moderate COVID-19 pneumonia.动态 CT 评估中度 COVID-19 肺炎患者的疾病变化和预后。
J Xray Sci Technol. 2020;28(5):851-861. doi: 10.3233/XST-200711.
5
Dynamic profile and clinical implications of hematological parameters in hospitalized patients with coronavirus disease 2019.住院的 2019 冠状病毒病患者血液学参数的动态特征及其临床意义。
Clin Chem Lab Med. 2020 Jul 28;58(8):1365-1371. doi: 10.1515/cclm-2020-0411.
6
Lymphopenia predicts disease severity of COVID-19: a descriptive and predictive study.淋巴细胞减少症可预测新型冠状病毒肺炎的疾病严重程度:一项描述性和预测性研究。
Signal Transduct Target Ther. 2020 Mar 27;5(1):33. doi: 10.1038/s41392-020-0148-4.
7
COVID-19 and liver disease.新型冠状病毒肺炎与肝脏疾病
Liver Int. 2020 Jun;40(6):1278-1281. doi: 10.1111/liv.14470.
8
Clinical Course and Outcomes of Patients with Severe Acute Respiratory Syndrome Coronavirus 2 Infection: a Preliminary Report of the First 28 Patients from the Korean Cohort Study on COVID-19.严重急性呼吸综合征冠状病毒 2 感染患者的临床病程和转归:来自韩国 COVID-19 队列研究的前 28 例患者的初步报告。
J Korean Med Sci. 2020 Apr 6;35(13):e142. doi: 10.3346/jkms.2020.35.e142.
9
Clinical course and mortality risk of severe COVID-19.重症新型冠状病毒肺炎的临床病程及死亡风险
Lancet. 2020 Mar 28;395(10229):1014-1015. doi: 10.1016/S0140-6736(20)30633-4. Epub 2020 Mar 17.
10
COVID-19: An Update on the Epidemiological, Clinical, Preventive and Therapeutic Evidence and Guidelines of Integrative Chinese-Western Medicine for the Management of 2019 Novel Coronavirus Disease.COVID-19:中西医结合管理 2019 年新型冠状病毒病的流行病学、临床、预防和治疗证据及指南的最新进展。
Am J Chin Med. 2020;48(3):737-762. doi: 10.1142/S0192415X20500378. Epub 2020 Mar 13.

COVID-19 患者在未经临床干预情况下的自然病程。

The natural course of COVID-19 patients without clinical intervention.

机构信息

Department of Infectious Diseases, The First Affiliated Hospital, Nanchang University, Nanchang, China.

出版信息

J Med Virol. 2021 Sep;93(9):5527-5537. doi: 10.1002/jmv.27087. Epub 2021 May 19.

DOI:10.1002/jmv.27087
PMID:33990975
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8242845/
Abstract

The natural course of coronavirus disease 2019 (COVID-19) patients without clinical intervention has not yet been documented. One hundred and fifty-eight patients from two hospitals were enrolled to identify the indicators of severe COVID-19 and observe the natural course of COVID-19 patients without clinical intervention. The total computed tomography (CT) score, a quantitative score based on assessment of the number, quadrant, and area of the lesions in CT, tended to perform better than assessment based only on the number or area of the lesions (p = 0.0004 and p = 0.0887, respectively). Multivariate logistic regression showed that the total CT score, chest tightness, lymphocyte, and lactate dehydrogenase (LDH) were independent factors for severe COVID-19. For patients admitted in 2 weeks from onset to hospitalization, the frequency of severe COVID-19 was gradually increased with the delayed hospitalization. The symptoms of fatigue, dry cough, sputum production, chest tightness, and polypnea were gradually more frequent. The levels of C-reactive protein, alanine aminotransferase, aspartate aminotransferase, total bilirubin, direct bilirubin, γ-glutamyl transpeptidase, LDH, and d-dimer were also gradually increased, as well as the scores based on CT. Conversely, the lymphocyte count and the albumin level were gradually decreased with the delayed hospitalization. Detail turning points of the above alterations were observed after 10-14 days from onset to hospitalization. Total CT score was a simple and feasible score for identifying severe COVID-19. COVID-19 patients without clinical intervention deteriorated gradually during the initial 10-14 days but gradually improved thereafter.

摘要

新冠肺炎患者在未经临床干预的情况下的自然病程尚未被记录。本研究纳入了来自两家医院的 158 名患者,旨在确定重症新冠肺炎的指标,并观察未经临床干预的新冠肺炎患者的自然病程。基于病变数量、象限和面积评估的总计算机断层扫描(CT)评分(一种定量评分),其表现优于仅基于病变数量或面积评估的评分(p = 0.0004 和 p = 0.0887)。多变量逻辑回归显示,总 CT 评分、胸闷、淋巴细胞和乳酸脱氢酶(LDH)是重症新冠肺炎的独立因素。对于从发病到住院的 2 周内入院的患者,随着住院时间的延迟,重症新冠肺炎的发生频率逐渐增加。疲劳、干咳、咳痰、胸闷和呼吸急促等症状逐渐更为频繁。C 反应蛋白、丙氨酸转氨酶、天冬氨酸转氨酶、总胆红素、直接胆红素、γ-谷氨酰转肽酶、LDH 和 D-二聚体的水平也逐渐升高,CT 评分也是如此。相反,随着住院时间的延迟,淋巴细胞计数和白蛋白水平逐渐降低。从发病到住院 10-14 天观察到上述变化的详细转折点。总 CT 评分是识别重症新冠肺炎的一种简单可行的评分。未经临床干预的新冠肺炎患者在最初的 10-14 天内逐渐恶化,但此后逐渐改善。